Connect your AI

Exelixis EXEL Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Eli LillyLLY

——

Summit TherapeuticsSMMT

——

IncyteINCY

——

BridgeBio PharmaBBIO

——

ALN

Alnylam PharmaceuticalsALNY

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exelixis's increase (decrease) in prepaid expense and other assets?: Exelixis (EXEL) reported increase (decrease) in prepaid expense and other assets of -$58.65M in Q1 2026.
How has Exelixis's increase (decrease) in prepaid expense and other assets changed year-over-year?: Exelixis's increase (decrease) in prepaid expense and other assets decreased by 188.6% year-over-year, from -$20.32M to -$58.65M.